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E-mail address: Bart.Staels@pasteur-lille.fr (B. StaeNuclear receptors (NRs) are molecular transducers of endocrine and dietary signals allowing tissues
to adapt their transcriptional responses to endogenous or exogenous cues. These signals act in many
cases as speciﬁc ligands, converting of NRs into transcriptionally active molecules. This on-off mech-
anism needs, however, to be ﬁnely tuned with respect to the tissue environment and adjusted to the
organism needs. These subtle adjustments of NR transcriptional activity are brought about by post-
translational modiﬁcations (PTMs), which can be, in the case of orphan NRs, the sole regulatory
mechanism. The role of PTMs, with a more speciﬁc focus on phosphorylation, affecting the functions
of NR controlling metabolic events is described in this review.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Nuclear receptors (NRs) regulate a wide range of biological pro-
cesses such as proliferation, apoptosis, differentiation and energy
homeostasis. These transcription factors are mostly known for
their ability to adjust the transcriptional activity of cells in re-
sponse to small hydrophobic ligands, which may emanate either
from the endocrine system (steroids, vitamin D, etc.) or from the
metabolic transformation of dietary compounds (cholesterol, fatty
acid derivatives, etc.) [1]. However, these ligand-regulated as well
as orphan NRs, for which no ligand has been yet identiﬁed [2], are
proteins integrating a number of other cellular signals stemming
from the activation of signaling cascades controlled by extracellu-
lar receptors. A wealth of data have enlightened the role of post-
translational modiﬁcations (PTMs) in modulating the functions of
NRs, among which phosphorylation seems to play a major role
[3]. In this respect, up to 30% of all human proteins may be modi-
ﬁed by kinase-directed modiﬁcations [4]. However, the literature
in the NR and other ﬁelds now clearly points to the existence of
interrelationships between phosphorylation and other PTMs such
as ubiquitination, SUMOylation, O-GlcNAcylation, and acetylationchemical Societies. Published by E
iversité Lille Nord de France,
9019 Lille, France. Fax: +33 3
ls).[5]. In this review, we will restrict our discussion to mechanisms
involving PTMs that regulate functions of NRs controlling meta-
bolic events.
NRs are a superfamily of transcription factors (48 in the human
genome) able to bind structurally diverse ligands such as steroid
and thyroid hormones, retinoic acid, vitamin D receptors, choles-
terol and fatty acid derivatives as well as xenobiotics. In most
cases, endogenous ligands act as agonists, thereby increasing the
transcriptional activity of the cognate NR, but it is likely that NRs
displaying a constitutively high transcriptional activity such as
estrogen-related receptors (ERRs) and constitutive androstane
receptor (CAR) might be regulated by endogenous inverse agonists.
NRs have an archetypical structure consisting of ﬁve or six func-
tional regions called A, B, C, D, E and F (Fig. 1). The amino terminus
(A/B domain) of the receptor encompasses the ligand-independent
transcriptional activation domain, called AF-1 (activation function-
1). The DNA binding domain (DBD or domain C) is a zinc-stabilized
structure highly conserved among the NRs, which contains two al-
pha-helices involved in DNA recognition and protein–protein
interaction. The D domain is a hinge region between domains C
and E involved in DNA recognition and allowing, owing to its struc-
tural ﬂexibility [6], NR dimers to bind to geometrically diverse DNA
response elements [hormone response elements (HRE)], now
known to occur most frequently in intronic and 30 UTR sequences
[7,8]. The C-terminal or E/F domain is the ligand-binding domain
(LBD) composed of 10–12 alpha-helices [9]. In addition to thelsevier B.V. All rights reserved.
Fig. 1. Schematic representation of different functional domains of a NR. DBD: DNA
binding domain; LBD: ligand binding domain; AF-1: activation function-1; AF-2:
activation function-2; A/B: activation domain of ligand-independent transcription;
C: DNA binding domain; D: hinge region; E: ligand binding domain.
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terminus of the LBD harbors the activation function (AF)-2 region,
which is a structure critical for the acquisition of transcriptional
activity by NRs. Ligand-binding induces conformational changes
in this region, creating a hydrophobic groove accommodating a
LXXLL peptidic structure ﬂanked by charged aminoacids which is
found on primary coactivators [10]. This initial event leads to the
build-up of a multiprotein transcriptional complex whose main
activity is to destabilize local chromatin structure and to propagate
signals from the NR binding site to the promoter of NR-regulated
promoters. The dimerization interface of NRs allows for, depending
on the NR, either homodimerization or heterodimerization with
retinoid X receptors (RXRs), which may be a pre-requisite for
DNA binding of many NRs [11,12]. This is however not an absolute
rule since some NRs such as FXR [13] or NR4As [14] can bind DNA
as monomers.
It is therefore rather intuitive to postulate that PTMs will intro-
duce structural constraints on NR functional domains and in turn
alter their transcriptional properties. As mentioned above, in view
of the large number of NRs and possible PTMs, we have chosen to
focus only on NRs involved in metabolic regulation (PPAR; LXR,
FXR, Rev-erb, ROR, Nurr7) and restrict our analysis to enzymes
catalyzing PTMs in response to metabolic signals.
2. Protein kinases and metabolism
Protein kinases catalyze the phosphorylation of proteins by
covalently adding phosphate groups to serine, threonine or
tyrosine residues. There are 27 families of protein kinases which
constitutes one of the largest and most important protein super-
families, totaling approximately 2000 protein kinases. The human
kinome is divided into nine groups: AGC kinases (PKA, PKC and
PKG), CaM kinases (calcium/calmodulin-dependent protein ki-
nases and CAMK-like kinases), CK1 (casein kinase 1 group), CMGC
(CDK, MAPK, GSK3 and CLK kinases), STE (homologs of yeast Sterile
7, Sterile 11, and Sterile 20 kinases), TK (tyrosine kinases), TKL
(tyrosine-kinase like group of kinases), atypical kinases (PDHK
and PIKK) and other unrelated kinases (such as IKK and CK2). In
this review, we focus below on protein kinases which can be mod-
ulated by altered metabolic states [cAMP-dependent kinase (PKA),
protein kinases C (PKCs); protein kinase B or Akt (Akt/PKB); mito-
gen-activated kinases (MAPKs), glycogen synthase kinase-3
(GSK3), AMP-activated protein kinase (AMPK)].
2.1. Protein kinase A
Protein kinase A (PKA) is a heterotetrameric cAMP-dependent
protein kinase, composed of two catalytic and regulatory subunits.
High levels of cAMP are sensed by regulatory subunits which re-
lease the catalytic subunit, and then interacts and modiﬁes its sub-
strates. Inactivation of the regulatory subunit II gene yield mice
resistant to high fat diet [15], and PKA has been shown to serve
several functions in cells, including the regulation of glycogen,
glucose, and lipid metabolism. The physiological effects of
glucagon are mediated by elevation of cellular cAMP levels and
activation of cAMP-dependent PKA [16], leading notably to thephosphorylation of the bifunctional enzyme PFK-2/F-2, 6-BiPhos-
phatase, hence favouring liver gluconeogenesis. In addition, expo-
sure for 14 days to increased glucose concentrations caused an
enhancement in cyclic AMP accumulation, PKA, and PKC activities
in human dermal microvascular endothelial cell line (HMEC-1)
[17]. Thus PKA is a kinase sensitive, among other stimuli, to meta-
bolic cues.
2.2. Akt/PKB
Akt, also called protein kinase B (PKB), is a serine/threonine pro-
tein kinase playing a key role in multiple cellular processes (glu-
cose metabolism, cell proliferation, apoptosis, transcription and
cell migration). Akt/PKBs are encoded by three highly homologous
genes with Akt1 being ubiquitously but most strongly expressed in
brain, heart, testis and thymus, while Akt2 is mostly restricted to
insulin-sensitive tissues and Akt3 essentially found in brain and
lungs [18]. Activation of Akt/PKB proceeds from the PI3K-
dependent conversion of phosphatidylinositol (4,5)-bisphosphate
(PIP2) to PIP3, allowing the anchoring of cytosolic Akt to the plas-
ma membrane and its phosphorylation by PDK-1 and the PDK2/
mTOR complex 2 on Thr308 and Ser473 respectively [19].
Activated Akt can then phosphorylate its numerous substrates
including GSK3, AMPK and the lipid metabolism regulator, sterol-
regulatory element-binding proteins (SREBPs) [20]. Gene inactiva-
tion studies concur to demonstrate the central role of the Akt/PKB
pathway as a critical regulator of glucose metabolism and insulin
sensitivity in response to stress and nutrients, thus placing its
downstream substrates under the control of these extracellular
signals. In addition, pathological conditions such as type II diabetes
are characterized by a reduced Akt signaling in human white adi-
pose tissue [21] and in the skeletal muscle from diabetic patients
and insulin-resistant Goto-Kakizaki rats [22]. Of note, Akt can itself
be regulated by PTMs: Akt2 is O-GlcNacylated, leading to impaired
phosphorylation and insulin resistance in rat primary adipocytes
[23]. Thus Akt/PKBs are, by virtue of their central role in conveying
adaptative cellular processes in response to extracellular signals
(nutrients, hormones, etc.) and intracellular environment varia-
tions (oxidative stress), upstream signaling kinases which will alter
the function(s) of their substrates in response to metabolic chal-
lenges. Interestingly, studies with a ﬂuorescent reporter showed
that PKB/Akt signaling propagates from the plasma membrane to
the nucleus [24], emphasizing a potential role in controlling tran-
scriptional events.
2.3. Protein kinases C
The PKC family can be divided into three groups: (i) conven-
tional PKCs (a, bI, bII, and c) requiring negatively charged phos-
pholipids, diacylglycerol (DAG) and calcium for their activity; (ii)
‘‘novel’’ PKCs l, g, h, e and d which require negatively charged
phospholipids, diacylglycerol but are calcium-independent; and
(iii) atypical PKCs k and n requiring only negatively charged phos-
pholipids. Each PKC differs in its primary structure, tissue distribu-
tion, subcellular localization, response to extracellular signals, and
substrate speciﬁcity [25]. Very schematically however, their mode
of activation relies on the same process. G-protein linked mem-
brane tyrosine kinases are activated by an extracellular signal,
triggering phospholipase C action on PIP2 to generate inositol-
1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 induces cal-
cium store release, whereas DAG activates membrane-bound PKC.
Quite clearly however, this long portrayed and simple mechanism
of activation by DAG is by far more complex and must take into ac-
count fatty acids, glycerolipids and sphingolipids as modulators of
PKC activity [26]. Depending on the activating signal, PKCs can
relocate to various subcellular compartments, including the Golgi
apparatus and the nucleus [27].
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Oxidative stress can either activate or inhibit PKC activity, depend-
ing on its intensity [28]. Bile acids, which play a critical role in
cholesterol and glucose metabolism [29], modulate the PKC path-
way via different mechanisms. In the absence of DAG, bile acids in-
crease PKC activity by promoting its association with
phospholipids [30]. Bile acids also stimulate phospholipase C activ-
ity, hence increasing DAG formation [31]. Glucose seems to be a
major modulator of PKC activity. During hyperglycemia, increased
DAG production correlates with an increased PKC b2 activity and
high glucose concentrations activate PKCa and PKCbI/2 in macro-
phages [32]. In human dermal microvascular endothelial cell line
(HMEC-1), glucose elevation cause an accumulation of cAMP, and
an increase in PKA and PKC activities [17]. In contrast, glucose de-
creases PKC activity by altering DAG kinase subcellular localization
in skeletal muscle [33]. As a result, chronic activation of PKC by
hyperglycemia is believed to be a cause of cardiovascular
complications in type 2 diabetic patients [34,35].
2.4. Mitogen-activated protein kinases
The mitogen-activated protein (MAP) kinase signaling cascade
is organized in several modules, including the extracellular sig-
nal-regulated kinase (ERK), p38, and c-Jun NH2-terminal kinase
(JNK). This vertical hierarchy is coupled to a layered structure,
comprising at least three levels (MAPK kinase kinase, MAPK kinase
and MAPK) which is biologically arranged as a multiprotein com-
plex in which scaffolding proteins such as kinase suppressor of
Ras-1 or JNK-interacting proteins (JIPs) play crucial roles [36]. As
described for other kinases therein, MAPKs display pleiotropic
activities which impact on multiple cellular processes. Whereas
the ERK module is principally activated through the Ras/Raf path-
way, the JNK and p38 modules are activated by deleterious signals
such as pro-inﬂammatory signals or oxidative stress. While the
role of these kinases has received considerable attention in the
cancer ﬁeld, it is now acknowledged that these signaling pathway
play also important roles in metabolic control, and are targets for
metabolic signals. Although the exact mechanisms are yet to be
deciphered, it is clear that excessive activation of these signaling
pathways participate to metabolic diseases [37].
2.5. AMP-activated protein kinase
Belonging to the CAMK branch of the kinome, AMPK is a het-
erotrimeric complex composed of isoforms of the catalytic a sub-
unit (a1 or a2), and the regulatory b (b1 or b2) and c (c1, c2 or
c3) subunits. AMP-activated protein kinase (AMPK) is a master
regulator of cellular energy homeostasis, behaving as a fuel sensor
activated when the cellular ATP/AMP ratio decreases as a result,
for example, of low glucose, hypoxia, ischemia, or heat shock
[38–40]. AMPK can be activated by two upstream pathways: a
Ca2+-dependent pathway mediated by CaMKKb and an AMP-
dependent pathway mediated by LKB1 [41]. The latter process oc-
curs through sensing of AMP levels by the c subunit, which in
turn renders the a catalytic subunit phosphorylatable by up-
stream activating kinases. Several studies identiﬁed adipokines
such as adiponectin and leptins as activators of AMPK [42],
strengthening its role as a regulator of energy balance, which is
also enlightened by its direct molecular interaction with a form
of cellular energy storage, glycogen [43], and its sensitivity to
pathophysiological conditions. AMPK regulates glucose metabo-
lism by promoting the translocation of the glucose transporter
(GLUT)-4 to the plasma membrane and AMPK activation improves
glucose homeostasis in animal model of insulin resistance [44].
Physiologically, exercise also activates AMPK and this activation
is believed to constitute one of the key mechanisms for thebeneﬁcial effect of physical training on glucose homeostasis,
which stems at least in part from transcriptional reprogramming
of metabolic tissues [45–47].
2.6. Gsk3
Unlike most of kinases, GSK3a and GSK3b are constitutively ac-
tive proline-directed serine/threonine-speciﬁc kinases which phos-
phorylate at SXXXS sites and are inhibited by phosphorylation [48].
Since its description, GSK3 has been shown to play a role in multi-
ple signaling pathways activated by the Wnt and Hedgehog path-
ways, growth factors and insulin. First described as glycogen
synthase kinase [49], a key enzyme in glycogen synthesis [50,51],
GSK3 is now known to phosphorylate dozens of substrates, includ-
ing transcription factors regulating inﬂammatory processes, cell
growth and differentiation [51]. GSK3 is inactivated by PKC, PKB/
Akt and PKA [52], exemplifying the complex interplay between ki-
nase-regulated pathways [51]. Insulin is, via PKB/Akt activation, a
GSK3 inactivating signal and GSK3 generally opposes the anabolic
effect of insulin. In agreement with this, GSK3 inhibitors have been
shown to have a positive effect on insulin sensitivity in preclinical
models of type 2 diabetes [53,54].3. Protein kinases and NRs
3.1. Peroxisome proliferator-activated receptors
The three peroxisome proliferator-activated receptor (PPAR)
isotypes (PPARa/NR1C1, b or d/NR1C2, and c/NR1C3) are encoded
by distinct genes. First shown to be activated by substances that in-
duce peroxisome proliferation in rodents [55,56], PPARs are acti-
vated by endogenous fatty acid derivatives and synthetic
normolipimiants (PPARa, ﬁbrates) or insulin sensitizers (PPARc,
thiazolidinediones). PPARs are involved in the control of metabolic
and energy homeostasis [57–59]. The expression of PPARa, b and c
varies widely from tissue to tissue, with PPARa being highly ex-
pressed in hepatocytes, cardiomyocytes, enterocytes, and the prox-
imal tubule cells of the kidney and involved mostly in fatty acid
oxidation. PPARb/d is expressed ubiquitously and often at higher
levels than PPARa and PPARc. PPARc, expressed predominantly
in adipose tissues and the immune system, exists as two distinct
isoforms c1 and c2 which arise from differential transcription start
sites and alternative splicing.
3.2. PPARa and PKC
The identiﬁcation of potential PKC phosphorylation sites in the
PPARa sequence prompted the investigation of the effect of this ki-
nase on PPARa transcriptional activity. The synthetic PKC activator
and DAG analog phorbol myristol acetate (PMA) increased the level
of phosphorylated PPARa. Inhibitors of PKC decreased agonist-
induced PPARa transactivation [60,61]. Overexpression of different
PKC isoforms (PKCa, -b, -d, and -f) affected both basal and agonist-
induced PPARa activity [62]. Blanquart et al. [60] and Gray
et al. [62] identiﬁed three PKC phosphorylation sites (T129, S179
and S230) required for ligand-induced PPARa transcriptional
activity. Interestingly, the loss in transactivating potential ob-
served upon alanine substitution of phosphorylated aminoacids,
which may relate to a blunted ability to heterodimerize with RXRa
[62], correlated to an increased transrepressive potential [60].
Intriguingly, the cholesterol synthesis inhibitor simvastatin
requires PPARa expression to exert its anti-inﬂammatory effects
in vivo. Simvastatin inhibited PPARa phosphorylation by
lipopolysaccharide-activated PKCa, resulting in enhanced PPARa
ability to transrepress the proinﬂammatory transcription factor
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wards transactivating instead of transrepressing activities.
3.3. PPARa and PKA
Cholera toxin and other PKA activators enhanced mouse PPARa
transcriptional activity in the absence and the presence of exoge-
nous ligands in transient transfection experiments. The main site
of phosphorylation is located in the DBD and the N-terminus of
PPARa is dispensable for PKA-mediated transcriptional activation
[64]. Thus PPARa activity is potentially modulated by physiological
cAMP modulators such as fasting, stress or exercise.
3.4. PPARa and MAPKs
PPARa activity modulates heart functions by increasing fatty
acid uptake and oxidation [65]. The p38 MAPK pathway is acti-
vated by cardio-myocyte stressors such as ischemia, hypoxia and
hypertrophic growth. p38 phosphorylates PPARa at its N terminus
(S6, 12 and 21) and increases PPARa transcriptional activity, prob-
ably through increased coactivator recruitment [66]. This estab-
lishes a plausible link, although not formally tested in vivo,
between PPARa, PTMs and cardiac function. In skeletal muscle,
adiponectin activates PPARa in an AMPK/p38 manner, which
may result in enhanced fatty acid oxidation hence improved
peripheral insulin sensitivity [67]. In contrast, anisomycin, a p38
activator, induced a dose-dependent phosphorylation of PPARa
and an inhibition of its transcriptional activity in COS-7 and in
H4IIE hepatoma cells [68]. Interestingly, the anabolic hormone
insulin also promotes PPARa activation through ERK-catalyzed
phosphorylation of the same residues (S12 and S21) in HepG2 hep-
atoma cells, but the physiological relevance of this PTM has not
been addressed [69].
Finally, co-transfection of MAPK phosphatase 1 (MKP-1) to-
gether with PPARa affects negatively its transcriptional activity
in a transient transfection assay [70]. Taken together, these studies
strongly hint at a general activating roles of MAPK on PPARa activ-
ity, thereby placing this NR under the control of growth factors and
various cellular stresses.
3.5. PPARa and AMPK
There is no evidence showing that AMPK directly phosphory-
lates PPARa. However, a number of studies reported the role of
AMPK as a PPARa coactivator in a kinase-independent manner
[71], a property reminiscent of the kinase-independent action of
PDK1 on PPARc transcriptional activity [72]. AMPK was also de-
scribed as a modulator of PPARa expression in response to glucose
levels or adiponectin [73–75]. This suggests that cellular energy
levels might regulate the PPARa-regulated signaling network in a
ligand-independent manner.
3.6. PPARc and MAPK
PPARc2 is phosphorylated in the A/B domain at S112 by MAPK
in response to several mitogenic growth factors that inhibit fat cell
differentiation. This phosphorylation reduces the transcriptional
activity of PPARc in adipocytes [76] and human omental fat [77],
which may result in part from the increased proteasomal degrada-
tion of PPARc [78] and/or decreased ligand-binding afﬁnity [79].
Moreover, ERK and JNK, which can be activated by TNFa and EGF
[80], phosphorylate S84 of the A/B domain of PPARc1 in vitro
and in turn inhibit both ligand-independent and ligand-dependent
transactivation functions [81]. However, this view was challenged
by a report showing that MEK1 can interact directly with the
PPARc AF2 domain and shuttle PPARc to the cytosol in aphosphorylation-independent manner [82], introducing a novel
paradigm on how kinases may regulate transcription factor activ-
ity. ERK1/2 mediated phosphorylation of PPARc was also shown
to favor the transrepressive activity of PPARc on NF-kappa-B
[83], further emphasizing the role of PTMs in specifying NR tran-
scriptional activities. Finally, the neighboring S82 (S112 of mouse
PPARc2) aminoacid is a target for JNK, which decreases PPARc1
transcriptional activity [84].
3.7. PPARc and PKA
In addition to the phosphorylation of PPARa and PPARb/d,
Lazennec et al. documented that PPARc transcriptional activity is
increased upon PKA activation [64].
3.8. PPARc and cdk5
Although widely acknowledged as a kinase involved in neuronal
architecture and functions, as well as in cell cycle regulation, cdk5
has signiﬁcant actions on the functions of pancreatic beta cells by
regulating glucose-stimulated insulin secretion, and as a molecular
relay for insulin-mediated glucose uptake in adipocytes [85]. The
activation of cdk5 in inﬂamed, obese white adipose tissues results
in the cdk5-dependent phosphorylation of PPARc at S273 and de-
creased PPARc activity. Furthermore, this phosphorylation-
dependent transcriptional extinction can be counteracted by
speciﬁc PPARc ligands, irrespective of their classiﬁcation as full
or partial agonists [86].
3.9. PPARc and CK2
The activity of NRs is conditioned by mechanisms affecting their
subcellular localization. CK-II-dependent PPARc1 phosphorylation
at Ser16 and Ser21 is necessary for CRM1/Ran/RanBP3-mediated
nucleocytoplasmic translocation of PPARc, which may constitute
a mechanism by which PPARc regulates negatively inﬂammatory
signaling pathways [87].
3.10. The nuclear bile acid receptor BAR/FXR
FXR is highly expressed in liver, intestine, kidney and adrenal
glands and weakly in adipose tissue [29]. Initially identiﬁed as a
receptor for farnesol [88], bile acids (BA) were later identiﬁed as
natural ligands of FXR [89,90]. In addition to its natural ligands
such as cholic acid and chenodeoxycholic acid, FXR can be acti-
vated by more speciﬁc synthetic ligands such as GW4064 and
fexaramine [91]. There are two FXR genes, FXRa (NR1H4) encoding
four major isoforms, and FXRb (NR1H5) which is a pseudogene in
humans but which encodes a receptor for lanosterol in other pri-
mates and rodents [92]. In addition to its hepato-protective action
against the cytotoxic effects of excessive bile acid concentrations,
FXR plays a crucial role in the enterohepatic recycling of bile acids,
in glucose and lipid metabolism [29].
3.11. FXR and PKC
Gineste et al. [93] showed that PKCa phosphorylates FXR in the
DBD at S135 and S154. This phosphorylation increases the tran-
scriptional activity of FXR by promoting recruitment of coactiva-
tors, such as PGC-1a [93]. Moreover, PKC activity is necessary for
a maximal ligand-dependent induction of FXR transcriptional
activity, in analogy with PPARa. Quite intriguingly, ATPase class I
type 8B member 1 (FIC1) expression favors PKCzeta-mediated
phosphorylation of FXR at S448 and controls FXR nucleocytoplas-
mic repartition, thereby exerting a positive control on FXR tran-
scriptional activity [94]. Interestingly, PKC can be modulated by
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such as bile acids, may sensitize FXR to their own ligand effect,
by inducing PKCa-mediated FXR phosphorylation, suggesting the
existence of a double, converging FXR activation pathway by bile
acids.
3.12. Liver X receptors
Liver X receptors (LXRa/NR1H3 and LXRb/NR1H2) function as
nutritional sensors for cholesterol and derivatives. LXRa is primar-
ily expressed in liver, macrophages, adipose tissue and the intesti-
nal epithelium, while LXRb is ubiquitously expressed [95].
Oxysterols, which are oxidized derivatives of cholesterol, are the
major ligands for LXR [96]. Glucose and glucose-6-phosphate have
also been reported as direct LXR agonists [97]. But this observation
has not been conﬁrmed [98]. In addition, unsaturated fatty acids,
such as arachidonic acid, may act as LXR antagonists. LXRs play
important roles in lipid metabolism, glucose homeostasis and
inﬂammation [99].
3.13. LXR and PKC
LXRa is phosphorylated by PKCa in vitro and pharmacological
activation of PKC by phorbol esters altered the transactivation of
LXRa, without altering the DNA binding activity [100].
3.14. LXR and PKA
Yamamoto et al. [101] showed that LXRa is phosphorylated by
PKA. Two consensus PKA target sites were identiﬁed in the ligand
binding/heterodimerization domain of LXRa (S195/196 and S290/
291). PKA-mediated phosphorylation at these sites inhibits li-
gand-mediated activation of LXR by a combined decrease in LXR/
RXR heterodimerisation, decreased coactivator and increased core-
pressor recruitment [101].
3.15. LXR and CK2
Although initially thought to be the major LXRa phosphoryla-
tion site in the hinge domain, S198 mutation had no reported
impact on LXR transactivation when assayed in HEK and RAW
cells on three LXR target genes (FAS, ABCA1 and ABCG1) [102].
In line with this, Torra et al. [103] showed that S198 in LXRa
is a CK2 phosphorylation site, which affects LXR-mediated trans-
activation on a limited subset of LXR target genes, including
CCL24, AIM and LPL, but not ABCA1, ABCG1, SREBP1c or PLTP
[103].
3.16. Nur77
Nur77 belongs to the NR4A orphan receptor subclass which also
includes Nor1 and Nurr1. Nurr77, Nor1 and Nurr1 bind to and acti-
vate transcription through ‘‘Nur77 Binding Response Elements’’
(NBRE) that display variable geometry [14]. Nur77, Nor1, and
Nurr1 can form homodimers, heterodimer or monomers on NBREs
to regulate yet poorly characterized direct target genes which have
been mostly identiﬁed in the central nervous system [104]. They
display inﬂammatory regulatory properties in the vascular wall
[105]. More recently, a metabolic role for these receptors has
emerged, with a speciﬁc emphasis on Nur77. This immediate early
gene (also called NGFI-B or TR3) was initially described as a regu-
lator of T cell antigen receptor-mediated cell death [106], but is
now known to regulate hepatic glucose [107] and lipid homeosta-
sis [108]. The lack of known ligand for Nur77 has sparkled intense
investigation of PTMs, as they appeared as major events regulating
Nur77 activity [109–111].3.17. Nur77 and Akt
In ﬁbroblast cell lines, Nur77 is phosphorylated at S350 in its
DBD by Akt/PKB, which interacts physically with Nur77. This
PI3K-dependent phosphorylation of Nur77 by Akt impinges nega-
tively on the transcriptional activity of Nur77 [112,113], which
may result from an increased nuclear export and tethering to
14.3.3 proteins [112,114]. A contradictory report, however, noted
that Nur77 was not phosphorylated by Akt, but by ribosomal S6 ki-
nase (RSK) or by mitogen and stress-activated kinase (RSK) in vitro
[115]. Intriguingly, membrane depolarization of PC-12 pheochro-
mocytoma cells also leads to S350 phosphorylation and Nur77
transcriptional deactivation [111].
3.18. Nur77 and PKA
Corticotrophin releasing hormone (CRH) is a central regulator of
the pituitary Nur77 target gene proopiomelanocortin (POMC). CRH
promotes PKA activation and subsequent DNA binding of Nur77 di-
mers, favoring NBRE-dependent transactivation of the POMC gene
through an increased tethering of coactivators to the N terminal
AF-1 [116]. This CRH-mediated activation of Nur77 was however
traced back to MAPK activation and MAPK-mediated Nur77 phos-
phorylation in an analogous system [117].
3.19. Hepatocyte nuclear factor-4
Hepatocyte nuclear factor-4 (HNF-4) is expressed in the liver,
gut, kidney and pancreatic beta cells. HNF-4 is critical for liver
development and mutations in the HNF4 gene form a monogenic
cause of maturity-onset diabetes of the young [118]. In humans,
there are two isotypes of HNF-4, alpha and gamma encoded by
two separate genes HNF4A and HNF4G, respectively. Linoleic acid
(LA) has recently been identiﬁed as the endogenous ligand of na-
tive HNF4 expressed in mouse liver [119]. From a molecular per-
spective, HNF-4 is viewed as a critical regulator of liver
differentiation and of hepatic genes involved in lipid and glucose
metabolism [120].
3.20. HNF-4 and PKA
HNF-4 is phosphorylated in vitro by PKA [121], and PKA activa-
tion leads to a decreased activation of HNF-4-regulated reporter
genes by HNF-4 [122]. Although this possibility has not been inves-
tigated, it is interesting to note that physiological effects of gluca-
gon are mediated by an elevation of cellular cAMP levels and
ensuing activation of cAMP-dependent PKA [16] and that this
would place HNF-4 under the control of pancreatic hormones.
However, HNF4 activity is also blunted by insulin through a
FoxO1-dependent mechanism [123], excluding the possibility of
simple, opposite effects of insulin and glucagon on HNF-4 activity.
3.21. Retinoid acid receptor-related orphan receptors (RORs)
The retinoid acid receptor-related orphan receptors (RORs) a, b
and c, initially referred to as RZRs, constitute a subfamily of nucle-
ar orphan receptors which regulate the expression of genes in-
volved in cellular differentiation by binding to ROR response
elements (ROREs) in the promoter regions of various genes [124].
RORa plays a role in development of cerebellar Purkinje cells,
smooth muscle cell differentiation and bone formation. It regulates
inﬂammatory responses, participates in the maintenance of circa-
dian rhythmicity [125], protects against atherosclerosis by and
regulates lipoprotein metabolism activating apolipoprotein A-I
and C-III gene transcription [126]. RevErba competes with RORa
for binding to the same target sequences and thus represents a
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RORb plays a role in retina maturation, whereas RORc participates
in the development of secondary lymphoid tissues [128].
3.22. ROR and PKC
RORa1 is highly expressed in Purkinje cells and conventional
PKC phosphorylates RORa and inhibits RORa transcriptional activ-
ity, but a causal link between these two phenomena has not yet
been demonstrated [129].
3.23. ROR and ERK2
RORa4 is phosphorylated by ERK2 in vitro in its hinge domain
at T128. U0126, an inhibitor of ERK1&2, completely suppressed
phosphorylation of RORa4 which was found to be inhibitory of
ROR transcriptional activity [127]. Interestingly, the MAPK cascade
is involved in the resetting of circadian gene expression [130], add-
ing a potential new layer of control on this complex regulatory
network.
3.24. Rev-erba
Rev-erba (NR1D1) and its paralog Rev-erbb (NR1D2) are en-
coded by two distinct genes. Unlike other members of the NR
superfamily, Rev-erbs are devoid of a ligand-dependent transacti-
vation activation domain-2 [130], and therefore behave as consti-
tutive transcriptional repressors by binding corepressors. More
recently, heme has been identiﬁed as a natural Rev-erb ligand.
They are expressed in most tissues and are particularly abundant
in liver, muscle, adipose tissue and the cerebellum. Their expres-
sion follows a robust circadian rhythm, since Rev-erb and RORa,
regulate clock genes such as BMAL. Rev-erbs are involved in vari-
ous biological processes such as adipocyte and muscle differentia-
tion, and regulation of lipid metabolism [131].
3.25. Rev-erba and GSK3
Rev-erba is phosphorylated at S55 and S59 by GSK3b and this
can be blocked by lithium, a treatment used in bipolar disorders.
This phosphorylation protects Rev-erba from proteosomal degra-
dation [132]. GSK3-mediated phosphorylation of Rev-erba may
thus constitute a potential molecular link between NR PTMs and
cyclical pathologies.4. Phosphorylation and other PTMs
4.1. Phosphorylation and SUMOylation
Small ubiquitin-like modiﬁcation (SUMOylation) is an impor-
tant PTM which modulates positively or negatively the activity,
the stability and the localization of intracellular proteins. SUMOy-
lation consists in the covalent modiﬁcation by SUMO proteins of
the e amino-group of lysine residues, and impinges on essential
cellular processes such as transcription factor activity and genome
stability [133,134]. The human genome encodes four small ubiqui-
tin-like modiﬁer isoforms called SUMO-1/2/3/4. The SUMO 2/3
proteins share 97% sequence identity, but only 50% sequence iden-
tity with SUMO-1. In mammals, SUMO-1/2/3 proteins are ubiqui-
tously expressed, whereas SUMO-4 is only expressed in kidney,
lymph nodes and spleen. In eukaryotic cells, about 10% of intracel-
lular proteins are SUMOylated. Protein SUMOylation is performed
by a cascade of three enzymes. First, the SUMO E1 enzyme SEA1/
2 activates mature SUMO proteins. Second, the activated mature
SUMO-protein is conjugated to the only SUMO E2 enzyme calledUbc9. The last step is the formation of a covalent link between
SUMO and lysine residue(s) of target proteins by one of the various
E3 ligases (PIAS family, HDAC4) [135,136]. Through this enzymatic
cascade, intracellular proteins can be tagged by monomeric SUMO-
1, multiple monomeric SUMO-2/3 or by polySUMO-2/3 chains. The
SUMOylation reaction is reversible through the activity of sentrin-
speciﬁc proteases (SENPs) [137]. In most cases, SUMOylation oc-
curs at W-K-x-E/D consensus sequences, W being an hydrophobic
aminoacid and x any aminoacid.
SUMOylation has been initially shown to be dependent on
phosphorylation of the heat shock factor HSF-1. A phosphoryla-
tion-dependent SUMOylation motif (PDSM) WKxExxSP has been
identiﬁed and found in 78 proteins, including the NR estrogen re-
lated receptors (ERRs), PPARc, thyroid hormone receptor TRb,
and the NR coactivator NCoA2 [138]. The notion of PDSM has been
extended to show that phosphorylation of aminoacids downstream
of the SUMO consensus sequence facilitates SUMOylation [139].
4.2. Phosphorylation-dependent SUMOylation of nuclear receptors
NRs are generally SUMOylated at a regular consensus sequence.
The overall concept emerging from these studies is that, like for
many other transcriptional regulators [133], SUMOylation inhibits
NR-mediated transactivation. In one case (RORa), SUMOylation
was shown to increase transcriptional activation [140]. Quite sur-
prisingly, SUMOylation is correlated to the acquisition by NR of a
more pronounced transrepressive activity, which correlates,
broadly speaking, to an increased anti-inﬂammatory activity of
the SUMOylated NRs. Initially dissected for PPARc [141], this con-
cept has been extended to many other NRs including LXRs, FXR and
ERRs [142].
A phospho-dependent SUMOylation has been described for sev-
eral NRs. A PDSM occurs in the orphan receptor TR2/NR2C2. TR2 is
phosphorylated at T210 by ERK2, and this stimulates K238
SUMOylation. This strengthens the interaction of TR2 with the
corepressor RIP140 and leads to the repression of TR2 target genes
[143].
The AF-1 domain of PPARc2 is composed of an activation and a
repression domain. PPARc2 is SUMO1-ylated in vivo, on K107 in
the repression domain [144]. A PPARc2 SUMOylation-defective
K107R mutant displays increased transactivation properties and
promotes adipocyte differentiation more efﬁciently. Phosphoryla-
tion of PPARc2 at S112 promotes K107 SUMOylation, which then
exerts more potent transrepressive effects [145,146] by targeting
PPARc to the promoter of Toll-Like Receptor-regulated target
genes and preventing corepressor clearance from these promoters
[141].
ERRa1 and ERRc2 have both PDSM sites located at the N-termi-
nus. Phosphorylation of S19 of ERRa1 increases SUMOylation at
K14, whose mutation to alanine increases ERRa activity [147]. Sim-
ilarly, inactivation of the N-terminal ERRc2 PDSM yields a superac-
tive receptor and conversely, mutations of neighboring,
phosphorylatable serine residues blunted ERRc2 activity [148].
4.3. Phosphorylation and ubiquitination
The ubiquitin–proteasome system (UPS) was discovered by Ir-
vin Rose, Avram Hershko and Aaron Ciechanover in 1970 [149].
By allowing the highly controlled funnelling of proteins to either
proteasomal degradation or other subcellular compartments, the
UPS is not surprisingly involved in all aspects of cellular processes.
The UPS is composed of about a thousand proteins (ubiquitin li-
gases, de-ubiquitinases, peptidases, etc.) that regulate ﬁnely ubiq-
uitination and degradation of proteins by the 26S proteasome.
Ubiquitin is a highly conserved peptide structure present in all
eukaryotic cells which is covalently linked to target proteins
1646 W. Berrabah et al. / FEBS Letters 585 (2011) 1640–1650through an enzymatic cascade very similar in its principle to the
SUMO cascade. First, ubiquitin is activated through the formation
of a thioester bond between ubiquitin and E1 activating
enzyme. The activated ubiquitin is then transferred to ubiquitin
conjugating enzymes (E2 or UBE) [150]. Ubiquitin ligases (E3) are
then required to bind ubiquitin to the targeted protein. A more
recently described enzyme (E4) facilitates the elongation of the
poly-ubiquitin chain. Ubiquitin speciﬁc peptidases (USP) catalyzes
the de-ubiquitination proteins and the recycling of ubiquitin
monomers [151].
The relationship between phosphorylation and ubiquitinylation
has been documented for several systems. One of them has re-
ceived particular intention due to its importance in inﬂammation,
the NF-kappa-B system. Quite schematically, cytosolic inhibitor
molecules (I-kappa-B) sequester active NF-kappa-B subunits in
the cytoplasm. Activation of this network by extracellular signals
leads to the rapid phosphorylation of I-kappa-B and its proteaso-
mal degradation [152]. Although not mandatory, phosphorylation
is thus very often preceding ubiquitin conjugation in cytosolic
and nuclear compartments [153].
4.4. Phosphorylation-dependent NR ubiquitinylation
Agonist binding triggers PPARc proteasomal degradation [150].
Likewise, IFNc promotes PPARc proteasomal degradation, a pro-
cess which is ERK-dependent and requires PPARc S112 phosphor-
ylation [78]. Rev-erba can be phosphorylated at S55 and S59 by
GSK3b, a PTM protecting rev-erba from proteasomal degradation
[132].
4.5. Phosphorylation and O-GlcNAcylation
O-GlcNAcylation consists in the attachment of a single N-ace-
tylglucosamine moiety via an O-b-glycosidic linkage to serine
and threonine residues. Glucosamine-6-phosphate, the precursor
of UDP-N-acetylglucosamine is synthesized by the hexosamine
biosynthetic pathway, which converts 3–5% of intracellular glu-
cose. The amount of O-GlcNAcylated proteins is therefore propor-
tional to the intracellular glucose content. O-GlcNAcylation is
catalyzed by a highly conserved and unique enzyme, uridine
diphospho-N-acetylglucosamine: polypeptide b-N-acetylglucos-
aminyltransferase (O-GlcNAc transferase, OGT). O-GlcNAcylation
is reversible through the action of b-N-acetylglucosaminidase (O-
GlcNAcase, OGA) [154]. Proteins can be O-GlcNAcylated in re-
sponse to stress, hormones or nutrients, and this follows in many
cases a competitive phosphorylation reaction at the same or
neighboring sites of proteins such as c-Myc and SP1 [155].
Moreover, a correlation between O-GlcNAcylation, ubiquitinationFig. 2. Effect of metabolic signalsand phosphorylation has been described for p53 [156], suggesting
a complex interplay between PTMs.
4.6. NR, phosphorylation and O-GlcNAcylation
There is little or no evidence for a competitive O-GlcNAcylation/
phosphorylation of ‘‘metabolic’’ NRs. The estrogen receptor beta
displays such an alternative, dynamic labeling at S16 located in a
PEST region, suggesting that these PTMs could regulate ERb stabil-
ity [157,158]. LXRa is O-GlcNAcylated and the AF-1 and DBD
regions are targeted by this PTM [159]. Since LXRa is phosphory-
lated by PKA, PKC and CK2 (see above) in these domains, one can
speculate that O-GlcNAcylation of LXRa may be affected by its
phosphorylation. Similarly, a bioinformatics search (PM and WB,
unpublished data) shows that S73 of PPARa is a potential O-GlcNA-
cylation site which is phosphorylated by GSK3 [160], again raising
the possibility of a dynamic PTM at this site.
5. Conclusions
NRs regulate, in many organisms, several biological functions
(growth, development, reproduction, metabolism, etc.). Protein
kinases, by phosphorylating NRs, play a key role in modulating
NR activity in pathophysiological contexts. The activity of protein
kinases is itself modiﬁed by the cellular metabolic status and envi-
ronment, therefore integrating NRs into a very complex regulatory
network (Fig. 2). This complexity is even increased when taking
into account the role of NRs as a physical assembly platform for
corepressor or coactivator complexes, which are also targets for
PTMs. This point has been addressed in recent reviews [161,162]
and will not be detailed here, but it is worth noting that these
comodulator complexes have enzymatic activities (acetylases and
methylases) which may affect NR themselves.
In addition, phosphorylation may not be the sole PTM acting at
a given site, but it may compete or act in synergy with other mod-
iﬁcations such as SUMOylation and ubiquitinylation which will tag
NRs for a distinct fate (Fig. 3). Beside proteasomal degradation,
these PTMs can target NRs to different subcellular localizations,
introduce steric hindrance in recognition surfaces that will prevent
essential functions of NRs such as dimerization, or convert the
receptor into a transrepressor. A full understanding of these very
complex patterns of regulation will require a complete character-
ization of the NR interactome and of its dynamic interactions with
modifying enzymes. This is undoubtedly one of the biggest chal-
lenges that the NR community is facing today, and this will be
made possible by the most recent and future technological devel-
opments in protein identiﬁcation by mass spectrometry, as well
as high throughput technologies in the cell biology ﬁeld.on kinases and NR activities.
Fig. 3. Cross-talk between phosphorylation and other PTMs.
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